Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III trial of VM202 in the patient with critical limb ischemia (CLI).

Trial Profile

Phase III trial of VM202 in the patient with critical limb ischemia (CLI).

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Donaperminogene seltoplasmid (Primary)
  • Indications Peripheral arterial disorders; Peripheral ischaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Nov 2017 New trial record
    • 12 Nov 2017 According to a ViroMed media release, IND has been approved by the China Food and Drug Administration.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top